InnoSer News
InnoSer joins the Eurostars funded project ‘LEMONAID’
LEMONAID takes on the challenge of developing a new drug against Diffuse Large B-Cell Lymphoma (DLBCL) tumors to ultimately reduce drug resistance and relapse potential for patients. InnoSer supports this ambition by its expertise in combined in-vitro and in-vivo...
InnoSer meets you at knowledge for growth event
Organized by flanders.bio since it's establishment in 2004, knowledge for growth brings over 1300 biotech, pharma, medtech, agricultural and chemical industry experts and decision makers, as well as investors, universities, topnotch research institutes, policymakers...
InnoSer welcomes Wim Tiest as its Chief Technology Officer
As of April 2020, Wim Tiest has joined InnoSer in the role of Chief Technology Officer (CTO) and as part of the company management team. Wim holds a MSc in biochemical engineering and in artificial intelligence, both from the KU Leuven. He has built his professional...
PDX/O oncology platform developments at InnoSer
Despite the challenging times for the life sciences sector during coronavirus restrictions, we’ve been fortunate enough and well prepared to continue with the development of our PDX/O platform for oncology research. On a weekly basis we receive patient tumor samples...
Press Release: InnoSer continues to deliver critical in-vivo and in-vitro services
Press release | Leiden, 19 March 2020 InnoSer continues to deliver critical in-vivo and in-vitro services COVID-19 restrictions call for attention to prevent fully halting life sciences operations InnoSer remains committed to continuing its in-vivo and in-vitro...
Taking Precautions Against Coronavirus
Following the most recent governmental advice and regulations, we have decided to take preventative measures against the fast spread of COVID-19. The health and interests of our customers, employees and other stakeholders are our top priority. In order to minimize the...
InnoSer and OrganoTherapeutics to Offer Midbrain Organoids
InnoSer is joining forces with OrganoTherapeutics to make midbrain organoids available for screening and development of pharmaceutical compounds. This partnership will enable providing midbrain organoids commercially as a platform for Parkinson’s disease research. CEO...
InnoSer and TheraIndx Strategic Partnership
InnoSer and TheraIndx announce their strategic partnership to better serve pharmaceutical and biomedical companies worldwide. Jan Bartels, the CEO of InnoSer, states: “Both companies offer unique service portfolios and bring a lot of aligned added value to our global...
InnoSer gets new cell culture facilities
InnoSer is expanding its infrastructure to better its in vitro services. These specialized services include syngeneic oncology models, PBMC and immune population work in vitro/ex vivo, organoid culture, PDX passage work and any in vitro compound screening on fresh...
Leap into the future; Development of a PDXO drug screening platform
Diepenbeek, December 10th 2018 – BioVille-InnoSer NV, a young and innovative Belgium based Contract Research Organization (CRO) has received an over € 1.6 million grant from the Flemish VLAIO. This development grant is awarded to set up a PDXO screening...
Interested In InnoSer’s Services?
Get in touch with us.